STAT· @statnews · X·· 15 天前AI 评分22
AI 导读
投资者和医生正热切等待Kymera一款实验性疗法的中期结果,该疗法被定位为Dupixent的竞争对手。https://trib.al/BkSER03
正文
Investors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent. https://trib.al/BkSER03
来源:STAT · x.com